Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Emcure Pharmaceuticals Ltd.
Change Company   
BSE Code 544210
ISIN Demat INE168P01015
Book Value 169.51
NSE Code EMCURE
Dividend Yield % 0.21
Market Cap 272897.55
P/E 63.44
EPS 22.69
Face Value 10  
27-Nov-2025 Emcure Pharmaceuticals informs about disclosure
22-Nov-2025 Emcure Pharmaceuticals informs about resignation ...
19-Nov-2025 Emcure Pharmaceuticals informs about investor pr...
10-Nov-2025 Emcure Pharma, Novo Nordisk India join hands to l...
06-Oct-2025 Emcure Pharmaceuticals surges on acquiring 20.42%...
04-Oct-2025 Emcure Pharmaceuticals acquires 20.42% stake in Z...
07-Aug-2025 Emcure Pharmaceuticals informs about outcome of b...
17-Jul-2025 Emcure Pharmaceuticals enters into agreement with...
17-Jul-2025 Emcure Pharmaceuticals gains on entering into agr...
10-Jul-2025 USFDA concludes PAI at Emcure Pharmaceuticals’ Gu...
04-Jul-2025 Emcure Pharmaceuticals incorporates wholly owned ...
04-Jul-2025 Emcure Pharmaceuticals informs about incorporatio...
23-Jun-2025 Emcure Pharmaceuticals jumps on getting nod for a...
21-Jun-2025 Emcure Pharmaceuticals gets nod for acquiring 20....
21-Jun-2025 Emcure Pharmaceuticals gets nod to incorporate wh...
Page 1 of 2
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.